Biogen Inc. shares, despite retail investor pessimism, rose 15.1% in 2025. Besides the successful launch of Leqembi, I highlight Skyclarys, an Nrf2 activator for the treatment of Friedreich's ataxia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback